These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 30518682)

  • 1. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
    Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS
    Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis.
    Bellos I; Frountzas M; Pergialiotis V
    Transfus Med Rev; 2020 Jul; 34(3):188-194. PubMed ID: 32819760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
    Schaefer B; Tobiasch M; Wagner S; Glodny B; Tilg H; Wolf M; Zoller H
    Bone; 2022 Jan; 154():116202. PubMed ID: 34534708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series.
    Seng NW; Barco JB; Wong MH; Lim KX; Peh WM; Ng CT; Cushway T; Foo FJ; Koh FH
    Transfus Med; 2023 Dec; 33(6):503-508. PubMed ID: 37263781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.
    Zhang F; Shen A; Ahmed W; Pollock RF
    Adv Ther; 2024 Nov; 41(11):4191-4204. PubMed ID: 39292421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.